Low molecular weight heparins: a developmental perspective

Bibliography

• FAREED J, WALENGA JM, KUMAR A, ROCK A: A modifiedstasis thrombosis model to study the antithrombotic actions of heparin and its fractions. Semin. Thromb. Hemost. (1985) 11:155.
   PubMed Web of Science ®Google Scholar
• FAREED J, HOPPENSTEADT D, HUAN X, RACANELLI A:Comparative study on the in vitro and in vivo activities of seven low molecular weight heparins. Hemostasis (1989) 18\(Suppl. 3):3.
   Google Scholar
• ABILDGAARD U, SANDSET P, LINDAHL A: Tissue factor pathway inhibitor. In: Recent Advances in Blood Coagula-tion. Poller L (Ed.), (1993):105–124.
   Google Scholar
• BROZE GJ: Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coag. Fibri-nol (1995) 6(1):S7.
   Google Scholar
• VAN DEDEM G, NIELSEN JI: Determinations of the mo-lecular mass of low molecular mass (LMM) heparin. Pharmeuropa (1991) 3:202–218.
   Google Scholar
• FAREED J, WALENGA JM, LASSEN M, BORRIS L, HOPPEN-STEADT DA: Pharmacologic profile of a low molecular weight heparin (Enoxaparin): experimental and clini-cal validation of the prophylactic antithrombotic ef-fects. Acta Chir. Scand (1990) 156\(Suppl. 556):75.
   Google Scholar
• CADE JF, BUCHANAN MR, BONEU B, OCKELFORD P: Acomparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the preparation. Thromb. Res. (1984) 35:613.
   PubMed Web of Science ®Google Scholar
• FAREED J, KUMAR A, ROCK A, WALENGA JM, DAVIS P: A primate model (Maraca mulatta) to study the pharma-cokinetics of heparin and its fractions. Semin. Thromb. Hemost. (1985) 11:138.
   PubMed Web of Science ®Google Scholar
• RAAKE W, ELLIN G H: Rat jugular vein hemostasis - a new model for testing antithrombotic agents. Thromb. Res. (1989) 53:73–77.
   PubMed Web of Science ®Google Scholar
• SAMAMA M: Contemporary laboratory monitoring of low molecular weight heparins. Thromb. Hemost (1995) 15 (1) :119–123.
   Google Scholar
• FAREED J: Current trends in antithrombotic drug and device development. Semin. Thromb. Hemost. (1996) 22 (1):3–8.
   PubMedGoogle Scholar
• CLAGETT GP, ANDERSON FA, Jr., HEIT J, LEVINE MN, WHEELER HB: Prevention of venous thromboembolism. Chest (1995) 108(4):3125–3345.
   Google Scholar
• PREMMEREUR J: The use of low-molecular-weight hepa-rins in cardiology. In: New Anticoagulants for the Cardio-vascular Patient Pifarré R (Ed.), Hanley & Belfus, Inc., Philadelphia (1997):597–608.
   Google Scholar
• KALODIKI E, NICOLAIDES AN: Low-molecular-weight heparin in the treatment of deep vein thrombosis. In: New Anticoagulants for the Cardiovascular Patient Pifarré R (Ed.), Hanley & Belfus, Inc., Philadelphia (1997):609–619.
   Google Scholar
• FAREED J, JESKE W, HOPPENSTEADT D, CLARIZIO R, WALENGA JM: Are the available low-molecular-weight heparin preparations the same? Semin. Thromb. Hemost (1996) 22\(Suppl. 0:77–91.
   Google Scholar
• HIRSH J, RASCHKE R, WARKENTIN TE et al: Heparin: mechanism of action, pharmacokinetics, dosing con-siderations, monitoring, efficacy, and safety. Chest (1995) 108(4):258S-275S.
   Google Scholar
• HIRSH J, HOAK J: Management of deep vein thrombosis and pulmonary embolism. Circulation (1996) 93(12)2212–2245.
   Google Scholar
• LECLERC JR, GEERTS WH, DESJARDINS L et al: Preventionof venous thromboembolism after knee arthroplasty. A randomized, double-blind trial lomparing Enoxa-pain with warfarin. Ann. Intern. Med. (1996) 124(7):619–626.
   Google Scholar
• BERGQVIST D, BENONI G, BJORGELL 0 et al: Low-mo-lecular-weight heparin (Enoxapain) as prophylaxis against venous thromboembolism after total hip re-placement. New Engl. J. Med. (1996) 335 (10):696–700.
   PubMed Web of Science ®Google Scholar
• LEVINE MN, GENT M, HIRSH J et al.: Ardeparin (low molecular weight heparin) was graduated compression stockings for the prevention of the thromboembolism. Arch. Inter. Med. (1996) 156:851–856.
   PubMed Web of Science ®Google Scholar
• HEIT JA, BERKOWITZ SD, BONA R et al: Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Thromb. Haemost. (1997) 77(0:32–38.
   PubMedGoogle Scholar
• PLANES A, VOCHELLE N, DARMON JY et al: Risk ofdeep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: dou-ble-blind randomised comparison of Enoxapain versus placebo. Lancet (1996) 348(9022)224–228.
   Google Scholar
• HULL RD, PINE() GF, BRANT RF: Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis. Clin. Appl. Thromb./Hemost. (1996) 2 (Suppl. 1):S4–S11.
   Google Scholar
• DAHL OE, ANDREASSEN G, ASPELIN T et al: Prolonged thromboprophylaxis following hip replacement sur-gery - results of a double-blind, prospective, random-ised, placebo-controlled study with dalteparin (Fragmin). Thromb. Haemost. (1997) 77 (0 :26–31.
   PubMedGoogle Scholar
• GARDLUND B FOR THE HEPARIN PROPHYLAXIS STUDY GROUP: Randomised, controlled trial of low-dose hepa-rin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet (1996) 347(9012): 1357–1361.
   PubMed Web of Science ®Google Scholar
• THE COLUMBUS INVESTIGATORS: Low molecular weight heparin is an effective and safe treatment for deep-vein thrombosis and pulmonary embolism. Blood (1996) 88(10 Suppl. 1):626a.
   Google Scholar
• FRAGMIN DURING INSTABILITY IN CORONARY ARTERY DISEASE (FRISC) STUDY GROUP: Low-molecular-weight heparin during instability in coronary artery disease. Lancet (1996) 347:561–568.
   PubMed Web of Science ®Google Scholar
• COHEN M, DEMERS C, GURFINKEL E et al.: Primary end-point analysis from the ESSENCE trial: Enoxapain versus unfractionated heparin in unstable angina and non-Q wave infarction. Circulation (1996) 94(8):I–554.
   Google Scholar
• ANTMAN EM, MCCABE CH, MARBLE SJ etal: Dose ranging trial of Enoxapain for unstable angina: results of TIMI 11A. Circulation (1996) 94(8)I–554.
   Google Scholar
• ZIDAR J: New insights in the prevention of thrombosis in coronary stents - the ENTICES trial and the role of Enoxapain. Ann. Hematol (1997) 4(Suppl. ID:A152.
   Google Scholar
• SCHIELE FJ, UILLEMENOT VAR, MENEVEAU NF eta].: Initialexperience of a sulphated pentasaccharide, a pure factor Xa inhibitor, in coronary angioplasty. Circulation (1996) 94 (8) J–742.
   Google Scholar
• HULL RD, RASKOB GE, PINEO GF et al Subcutaenous low-molecular-weight heparin compared with continu- ous intravenous heparin in the treatment of proximal vein thrombosis. New Engl. J. Med. (1992) 326(15)975–982.
   Google Scholar
• PRANDONI P, LENSING AWA, BeLLER HR etal.: Compari-son of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet (1992) 339:441–445.
   Google Scholar
• LOPACIUK S, MEISSNER AJ, FILIPECKI S et al.: Subcutane-ous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb. Haemost. (1992) 68:14–18.
   PubMed Web of Science ®Google Scholar
• LINDMARKER P, HOLMSTROM M, GRANQVIST S, JOHNSSON H, LOCKNER D: Comparison of once-daily subcutaneous Fragmin with continuous inhavenous unfractionated he parin in the treatment of deep venous thrombosis. Thromb. Haemost. (1994) 72:186–190.
   PubMed Web of Science ®Google Scholar
• SIMONNEAU G, CHARBONNIER B, DOCOUSUS H et al.: Subcutaneous low molecular weight heparin compared with continuous intravenous unfractioned heparin in the treatment of proximal deep vein thrombosis. Arch. Intern. Med (1993) 153(13):1541–1546.
   PubMed Web of Science ®Google Scholar
• RASKOB GE: Low molecular weight heparin for the prevention and treatment of venous thromboem-bolism. Curr. Opin. Pulmon. Med. (1996) 2(0305–310.
   PubMedGoogle Scholar
• KOOPMAN MMW, PRANDONI P, PIOVELLA F eta].: Treat-ment of venous thrombosis with intravenous unfrac-tionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. New Engl. J. Med. (1996) 334 (10:682–687.
   Google Scholar
• LEVINE M, GENT M, HIRSH J et al: A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. New Engl. J. Med. (1996) 334(10:677–681.
   PubMedGoogle Scholar
• GODWIN J: Use of low molecular weight heparins in malignancy-related thromboembolic disorders: a clini-cal review. Clin. Appl. Thromb./Hemost (1996) 2 (Suppl. 1):S28–S34.
   Google Scholar
• FRICKER JP, VERGNES Y, SCHACH R et al: Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Eur. Clin. Invest. (1988) 18:561–567.
   PubMed Web of Science ®Google Scholar
• ENKE A, BREDDIN K: Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients under-going abdominal surgery. Br. J. Surg. (1988) 75:1058.
   PubMed Web of Science ®Google Scholar
• GODWIN JE, COMP P, DAVIDSON B et al: Comparison of the efficacy and safety of subcutaneous RD heparin versus subcutaneous unfractionated heparin for the prevention of deep-vein thrombosis in patients under-going abdominal or pelvic surgery for cancer. Thromb. Haemost (1996) 69:376.
   Google Scholar
• PRANDONI P, LENSING AWA, BOLLER HR etal.: Dee p-ve in-thrombosis and the incidence of subsequent sympto-matic cancer. New Engl. J. Med. (1992) 327:1128–1133.
   Google Scholar
• MONREAL M, LAFOZ E, OLIVE A, DEL RIO L, VEDIA C: Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contrain-dications to coumarin. Thromb. Haemost. (1994) 71:7–11.
   PubMed Web of Science ®Google Scholar
• SALAZAR E, IZAGUIRRE R, VERDEJO J, MUTCHINICK 0: Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant pa-tients with mechanical cardiac valve prostheses. J. Am. Coll. Cardiol (1996) 127(7):1698–1703.
   Google Scholar
• HUNT BJ, DOUGHTY H-A, MAJUMDAR G et al.: Throm-boprophylaxis with low molecular weight heparin (fragmin) in high risk pregnancies. Thromb. Haemost (1997) 77(0:39–43.
   PubMedGoogle Scholar
• BODA Z, LASZLO P, REJTO L eta].: Low molecular weight heparin as thromboprophylaxis in familial thrombo-philia during the whole period of pregnancy. Thromb. Haemost (1996) 76(0:124–128.
   Google Scholar
• MASSICOTTE P, ADAMS M, MARZINOTTO V, BROOKER LA, ANDREW M: Low-molecular-weight heparin in pediatr ic patients with thrombotic disease: a dose finding study. Pediatr. (1996) 128:313–318.
   Web of Science ®Google Scholar
• FORRAT R, FERRERA R, BOISSONNAT P et al.: High prevalence of thromboembolic complications in heart transplant recipients. Transplantation (1996) 61 (5) 757–762.
   PubMed Web of Science ®Google Scholar
• WALENGA JM, KOZA MJ, LEWIS BE, PIFARRE R: Relativeheparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin. Appl. Thromb./Hemost (1996) 2 (Suppl. 1):S21–S27.
   Google Scholar
• GREINACHER A, FEIGL M, MUELLER-ECKHARDT C: Cross-reactivity studies between sera of patients with heparin associated thrombocytopenia and a new low molecular weight heparin, reviparin. Thromb. Haemost. (1994) 72(4)644–645.
   Google Scholar
• GREINACHER A, ALBAN S, DUMMEL V, FRANZ G, MUEL-LER-ECKHARDT C: Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb. Haemost (1995) 74(3):886–892.
   PubMed Web of Science ®Google Scholar
• WARKENTIN TE, LEVINE MN, HIRSH J eta].: Heparin-in-duced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. New Engl. J. Med. (1995) 332(20):1330–1335.
   Google Scholar
• FAREED J, WALENGA JM, HOPPENSTEADT D, HUAN X, NONN R: Biochemical and pharmacologic inequiva-lence of low molecular weight heparins. Ann. NY Acad. Sci. (1989) 556:333–353.
   PubMed Web of Science ®Google Scholar
• FAREED J, CALLAS DD, HOPPENSTEADT D, JESKE W, WALENGA JM: Recent developments in antithrombotic agents. ap. Opin. Invest. Drugs (1995) 4(5):389–412.
   Google Scholar
• BRIEGER D, DAVVES J: Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins. Thromb. Haemost (1997) 77(2)317–322.
   Google Scholar
• COLLIGNON F, FRYDMAN A, CAPLAIN H eta].: Compari-son of the pharmacokinetic profiles of three low mo-lecular mass heparins - dalteparin, Enoxapain and nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboem-holism) Thromb. Haemost. (1995) 73(4):630–640.
   Google Scholar
• ERIKSSON BI, SODERBERG K, WIDLUND L et a].: A comparative study ofthree low-molecular weight hepa-rins (1,111WH) and unfractionated heparin (UH) in healthy volunteers. Thromb. Haemost. (1995) 73 (3):398–401.
   Google Scholar
• BONEU B: Low molecular weight heparin therapy: ismonitoring needed? Thromb. Haemost. (1994) 72(3):330–334.
   Google Scholar
• SAMAMA M: Contemporary laboratory monitoring of low molecular weight heparins. Thromb. Haemost (1995) 15(0:119–123.
   Google Scholar
• HOPPENSTEADT DA, JESKE W, FAREED J: Laboratory monitoring of new anticoagulant and antithrombotic drugs. In: New Anticoagulants for the Cardiovascular Pa-tient. Pifarré R (Ed.), Hanley & Belfus, Inc., Philadelphia (1997):521–538.
   Google Scholar
• HAWKINS DW: Global economic perspective on the useof low molecular weight heparin. Clin. Appl. Thromb./He-most. (1996) 2 (Suppl. 1):S40–S43.
   Google Scholar
• HULL RD, FELDSTEIN W, STEIN PD, PINEO GF: Cost-effec-tiveness o f pulmonary embolism diagnosis. Arch. Intern. Med. (1996) 156:68–72.
   PubMed Web of Science ®Google Scholar
• BARROWCLIFFE TW: Low molecular weight heparins. Br. J. Hematol (1995) 90:1.
   PubMed Web of Science ®Google Scholar
• LINDAHL AK, ABILGAARD U, LARSEN ML et al.: Extrinsic pathway inhibitor (EPO and the post-heparin antico-agulant effect in tissue thromboplastin-idncued coagu-lation. Thromb. Res. (1991) 64:155.
   PubMed Web of Science ®Google Scholar
• ABILDGAARD U: Relative role of tissue factor pathway inhibitor and antithrombin in the control of thrombo-genesis. Blood Coag. Fibrinol (1995) 6:545.
   Google Scholar
• BROZE GJ, Jr.: Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coag. Fibri-nol. (1995) 6:S7.
   Web of Science ®Google Scholar
• HOPPENSTEADT DA, JESKE W, FAREED J, BERMES EW, Jr.: The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low molecular weight heparin. Blood Coag Fibrinol (1995) 6:S57.
   Google Scholar
• BOGNACKI J, HAMMELBURGER J: Functional and immu-nologic methods for the measurement of human tissue factor pathway inhibitor. Blood Coag. Fibrinol. (1995) 6:S65.
   PubMed Web of Science ®Google Scholar
• LINDAHL AK, SANDSET PM, ABILDGAARD U: The presentstatus of tissue factor pathway inhibitor. Blood Coag. Fibrinol (1992) 3:439.
   PubMed Web of Science ®Google Scholar
• PETERSEN CC, BJORN SE, NORDFANG 0: Effect of leuko-cyte proteinases on tissue factor pathway inhibitor. Thromb. Haemost (1992) 67:537.
   PubMed Web of Science ®Google Scholar
• JESKE W, HOPPENSTEADT D, KLAUSER R et al.: Effect of repeated aprosulate and Enoxapain administration on TFPI antigen levels. Blood Coag. Fibrinol (1995) 6:119.
   PubMed Web of Science ®Google Scholar
• HOPPENSTEADT D, WALENGA JM, FASANELLA A, JESKE W, FAREED J: TFPI antigen levels in normal human volunteers after intravenous and subcutaneous admini-stration of unfractionated heparin and a low molecular weight heparin. Thromb. Res. (1995) 77(2):175.
   PubMed Web of Science ®Google Scholar
• FAREED J: Basic and applied pharmacology of low molecular weight heparins. Pharm. Ther. (1995) 16s–24s.
   Google Scholar
• FAREED J, CALLAS D, HOPPENSTEADT D, JESKE W, WALENGA JM: Recent developments in antithrombotic agents. Invest. Exp. Opin. Drugs (1995) 4:389–412.
   Google Scholar
• FAREED J, WALENGA JM, HOPPENSTEADT DA, RACANELLI A, COYNE E: Chemical and biochemical heterogeneity in low molecular weight heparins: implications for clinical use and standardization. Semin. Thromb. Hem ost (1989) 15:440.
   PubMed Web of Science ®Google Scholar
• FAREED J, CALLAS D, HOPPENSTEADT D, JESKE W, WALENGA JM: Recent developments in antithrombotic agents. Exp. Opin. Invest. Drugs (1995) 4:389.
   Google Scholar
• FAREED J, WALENGA JM, PIFARRE R: Newer approaches to the pharmacologic management of acute myocardial infarction. Cardiac Surg. State of the Art Reviews (1992) 6:101.
   Google Scholar
• HIRSH J, S1RAGUSA S, COSMI B, GINSBERG JS: Low mo-lecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism. Thromb. Haemost. (1995) 74:360–363.
   PubMed Web of Science ®Google Scholar
• HANKE H, OBERHOFF M, HANKE S et al: Inhibition of cellular proliferation after experimental balloon angioplasty by low molecular weight heparin. Circula-tion (1992) 85:1548.
   PubMed Web of Science ®Google Scholar
• SCHMID KM, PREISACK M, VOELKER W, SUJATTA M, KARSCH KR: First clinical experience with low molecu-lar weight heprin LU 47311 (Reviparin) for prevention of restenosis after per cutaneous transluminal coronary angioplasty. Semin. Thromb. Hemost (1993) 19:155.
   PubMed Web of Science ®Google Scholar
• KAKKAR VV: Effectiveness and safety of low molecular weight heparins (LMWH) in the prevention of venous thromboembolism (VTE). Thromb. Haemostas. (1995) 74:368.
   Google Scholar
• FAREED J, HOPPENSTEADT D, WALENGA JM: A perspec-tive on low molecular weight heparins in the manage-ment of thrombosis. Haemostaseologie (1993) 13:S5.
   Google Scholar
• Differentiation of beef and pig mucosal heparins by NMR spectroscopy [letter]. Thromb. Haemostas. (1995) 74:1197–1207.
   PubMedGoogle Scholar
• FAREED J, HOPPENSTEADT D, IYER L: Impact of biotech-nology in the diagnostic and therapeutic management of cardiovascular disorders. In: Nutrition and Biotechnol-ogy in Heart Disease and Cancer. Longnecker JB (Ed), Plenum Press, New York (1995).
   Google Scholar
• AGNELLI G, IORLO A, RENGA C et al: Prolonged an-tithrombin activity of low molecular weight heparins. Clinical implications for the treatment of thromboem-bolic diseases. Circulation (1995) 92:2819–2824.
   Google Scholar
• HIRSH J, RASCHKER R, WARKENTIN TE et al.: Chest (1995) 108(4):258S-275S.
   Google Scholar